GlaxoSmithKline Patents – Insights & Stats

GlaxoSmithKline has a total of 14306 patents globally, out of which 4376 have been granted. Of these 14306 patents, more than 70% patents are active. United States of America is where GlaxoSmithKline has filed the maximum number of patents, followed by Europe and Japan and it also seems reasonable as the biggest market for GlaxoSmithKline is USA & Europe. Parallelly, USA & Europe seems to be the main focused R&D center and United Kingdom is the origin country of GlaxoSmithKline.

GlaxoSmithKline was founded in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. The company doing business in Pharmaceuticals, Biotechnology and Consumer goods Industry. The Company offers a wide range of products in Pharmaceutical and Consumer healthcare. As of December 2021, GlaxoSmithKline has a market cap of $107.37 Billion.

Do read about some of the most popular patents of GlaxoSmithKline which have been covered by us in this article and also you can find GlaxoSmithKline patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over GlaxoSmithKline patent portfolio.

How many patents does GlaxoSmithKline have?

GlaxoSmithKline has a total of 14306 patents globally. These patents belong to 2162 unique patent families. Out of 14306 patents, 9982 patents are active.

How many GlaxoSmithKline patents are Alive/Dead?

Worldwide Patents

Glaxosmithkline Patent Portfolio

How Many Patents did GlaxoSmithKline File Every Year?

Glaxosmithkline Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantGSK Applications FiledGSK Patents Granted
20111521
201219859
2013158249
20141619227
20151664351
20161653582
20171483712
20181356680
2019764696
2020431587
2021129483

Which GlaxoSmithKline Drug Patents are Expiring in the Next 10 Years?

The patent no. US8113199B2 which is expiring in Oct, 2027, describing a helpful dose counter is designed to minimize false counts and tampering risks. It consists of a rotating index wheel with recesses and an indexer that accurately counts and tracks individual medicine doses on the carrier.

Given below is the list of few drugs patented by GlaxoSmithKline accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
Breo ElliptaUS8113199B2Counter For Use With A Medicament…Oct, 2027
ZejulaUS11673877B2Niraparib CompositionsMar, 2038
JesduvroqUS8557834B2Prolyl Hydroxylase InhibitorsJun, 2027
NicoretteUS8501164B2Nicotine Lozenge CompositionsJun, 2029
Lamictal OdtUS7919115B2Orally Disintegrating Tablet…Jan, 2029

How Many Patents did GlaxoSmithKline File in Different Countries?

Glaxosmithkline Worldwide Patents

Countries in which GlaxoSmithKline Filed Patents

CountryPatents
United States Of America1641
Europe1219
Japan989
China786
Canada777
Australia746
Brazil603
Korea (South)518
United Kingdom351
Spain341
Singapore310
Mexico308
Israel303
Russian Federation279
Taiwan234
Eurasian Patent Organization223
Argentina210
Peru167
India159
South Africa154
Chile152
Hong Kong (S.A.R.)141
Philippines128
Thailand127
Portugal126
Denmark119
Morocco119
Uruguay118
Poland118
Costa Rica116
Dominican Republic108
Colombia106
Croatia103
Hungary100
Slovenia100
Lithuania91
Belgium88
New Zealand75
Serbia75
Cyprus61
Ukraine52
Viet Nam51
Indonesia48
Turkey40
Montenegro38
Malaysia32
San Marino18
Jordan18
Germany12
Norway11
Ireland9
Gulf Cooperation Council7
Tunisia5
African Regional Industrial Property Organization5
Italy4
France4
Saudi Arabia2
Netherlands1
Ecuador1
Honduras1
Guatemala1
Republic of Moldova1
Luxembourg1
Nicaragua1

Where are Research Centers of GlaxoSmithKline Patents Located?

Research Centers of GlaxoSmithKline Patents

10 Best GlaxoSmithKline Patents

WO2011140324A1 is the most popular patent in the GlaxoSmithKline portfolio. It has received 232 citations so far from companies like Epizyme, Janssen Sciences Ireland, Novira Therapeutics and Pfizer.

Below is the list of 10 most cited patents of GlaxoSmithKline:

Publication NumberCitation Count
WO2011140324A1232
WO2014179620A1226
WO2012006380A2171
WO2011140325A1169
WO2012005805A1166
WO2013029338A1163
WO2012158613A1149
WO2012163805A1147
WO2012006376A2144
WO2011161031A1142

Which Companies are using GlaxoSmithKline Patents to Advance their Research?

If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.

The top citing companies in the GlaxoSmithKline patent portfolio are IBM, Neurometrix and Modernatx Inc.

List of the top forward citing Companies –

CompanyNumber of Patents
IBM9
Neurometrix8
Modernatx Inc7
Ionis Pharmaceuticals7
Janssen Pharmaceuticals7
Roche Innovation Center6
Bristol-Myers Squibb4
Genentech4
Pfizer3
Biopharma Credit3

Count of 102 and 103 Type Rejections based on GlaxoSmithKline Patents

Top GlaxoSmithKline Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US9127276B211
US20130118255A19
US20110215931A19
US8948876B28
US8853408B27
US10279179B26
US8642752B26
US9181549B25
US9740549B25
US20140193517A15
US9827420B25
US20110218756A14
US9295646B24
US20130192356A14
US10286037B24

What Percentage of GlaxoSmithKline US Patent Applications were Granted?

GlaxoSmithKline (Excluding its subsidiaries) has filed 2285 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1443 have been granted leading to a grant rate of 68.0%.

Below are the key stats of GlaxoSmithKline patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for GlaxoSmithKline?

Law FirmTotal ApplicationsSuccess Rate
Glaxosmithkline157066.28%
Novartis Pharmaceutical Corporation13637.62%
Birch Stewart Kolasch & Birch5974.36%
Morrison & Foerster4556.82%
Mccarter & English2985.71%
Smithkline Beecham27100.00%
Foley & Lardner1668.75%
Seed Intellectual Property Law Group1678.57%
James M Kanagy15100.00%
Mcdermott Will & Emery1569.23%

“We are a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better, live longer.”

GSK has made significant investments in scientific and technical expertise in order to develop and launch a pipeline of novel drugs that address the needs of patients, payers, and consumers. In the year 2020, GSK had invested £4.6 billion in R&D.

Each of GSK’s three businesses, which discover, develop, and manufacture revolutionary pharmaceutical medicines, vaccines, and consumer healthcare products, contributes to the company’s long-term priorities of Innovation, Performance, and Trust.

GSK’s approach to Pharmaceutical Research and Development (R&D) is driven by the multiplier impact of Science x Technology x Culture and focuses on immune system science, human genetics, and innovative technology. It will assist GSK in speeding up the development and delivery of transformative medicines by prioritising compounds with a higher chance of success and cancelling less promising programmes. It also allows the company to focus more on specialty medications, such as cancer.

GSK’s Vaccines division seeks to protect more people by expanding indications and delivering vaccines to new areas while balancing its focus on a solid pipeline with active life-cycle management of its existing vaccines. The company’s Innovation goal is to disrupt the vaccine discovery, development, and manufacturing processes in order to lead the industry. It will concentrate on advancing important assets in its pipeline and exploring novel technologies in order to capitalise on emerging fields’ potential. It is speeding the delivery of its most promising assets to meet the highest unmet medical need by leveraging its industry-leading science.

Oral Health, Pain Relief, Respiratory, Nutrition, Gastrointestinal and Skin Health are the five categories in which GSK’s Consumer Healthcare R&D group creates products. Its primary goal is to develop a robust, competitive pipeline of consumer-driven, science-based innovation.

EXCLUSIVE INSIGHTS COMING SOON

What are GlaxoSmithKline key innovation segments?

What Technologies are Covered by GlaxoSmithKline?

The chart below distributes patents filed by GSK in different countries on the basis of the technology protected in patents. It also represents the markets where GSK thinks it’s important to protect particular technology inventions

R&D FocusHow GlaxoSmithKline search focus changed over the years?

Interested in knowing about the areas of innovation that are being protected by GlaxoSmithKline?

EXCLUSIVE INSIGHTS COMING SOON

Related Articles

Hayco Patents – Insights & Stats (Updated 2024)

Hayco has a total of 156 patents globally, out of which 123 have been granted. Of these 156 patents, more than 12% patents are active. United States of America is where Hayco has filed the maximum number of patents, followed by China and Europe (EPO). Parallelly, China seems to be

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.